MX2009007198A - Uso de compuestos neuroprotectores para obtener medicamentos destinados al tratamiento de enfermedades neurodegenerativas. - Google Patents

Uso de compuestos neuroprotectores para obtener medicamentos destinados al tratamiento de enfermedades neurodegenerativas.

Info

Publication number
MX2009007198A
MX2009007198A MX2009007198A MX2009007198A MX2009007198A MX 2009007198 A MX2009007198 A MX 2009007198A MX 2009007198 A MX2009007198 A MX 2009007198A MX 2009007198 A MX2009007198 A MX 2009007198A MX 2009007198 A MX2009007198 A MX 2009007198A
Authority
MX
Mexico
Prior art keywords
neurodegenerative diseases
treating neurodegenerative
neuroprotective compounds
obtaining drugs
drugs
Prior art date
Application number
MX2009007198A
Other languages
English (en)
Inventor
Alain Le Ridant
Catherine Harpey
Original Assignee
Servier Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Servier Lab filed Critical Servier Lab
Publication of MX2009007198A publication Critical patent/MX2009007198A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/06—Peri-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Uso de compuestos neuroprotectores para obtener medicamentos destinados al tratamiento curativo de enfermedades neurodegenerativas y/o a la prevención de la aparición de problemas que se derivan de estas enfermedades.
MX2009007198A 2007-01-05 2008-01-04 Uso de compuestos neuroprotectores para obtener medicamentos destinados al tratamiento de enfermedades neurodegenerativas. MX2009007198A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0700048A FR2911143A1 (fr) 2007-01-05 2007-01-05 Utilisation de composes neuroprotecteurs pour l'obtention de medicaments destines au traitement de maladies neurodegeneratives.
PCT/FR2008/000014 WO2008099083A2 (fr) 2007-01-05 2008-01-04 Utilisation de composes neuroprotecteurs pour l'obtention de médicaments destines au traitement de maladies neurodegeneratives

Publications (1)

Publication Number Publication Date
MX2009007198A true MX2009007198A (es) 2009-08-12

Family

ID=38309971

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009007198A MX2009007198A (es) 2007-01-05 2008-01-04 Uso de compuestos neuroprotectores para obtener medicamentos destinados al tratamiento de enfermedades neurodegenerativas.

Country Status (14)

Country Link
US (1) US20090298813A1 (es)
EP (1) EP2101768A2 (es)
JP (1) JP2010514827A (es)
KR (1) KR20090104853A (es)
CN (1) CN101578100A (es)
AR (1) AR064749A1 (es)
AU (1) AU2008214550A1 (es)
BR (1) BRPI0806275A2 (es)
CA (1) CA2674100A1 (es)
EA (1) EA200900923A1 (es)
FR (1) FR2911143A1 (es)
MA (1) MA31032B1 (es)
MX (1) MX2009007198A (es)
WO (1) WO2008099083A2 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2926077A1 (fr) * 2008-01-04 2009-07-10 Servier Lab Nouveaux derives d'1h-indol-1-yl uree, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
JP6154282B2 (ja) * 2013-10-03 2017-06-28 株式会社ファンケル 神経幹細胞又は神経前駆細胞の増殖促進剤
CN111018802B (zh) * 2019-12-03 2021-07-06 湖北大学 具有抗帕金森氏症的化合物、制备方法及其应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA786426B (en) * 1977-11-25 1979-10-31 Scras New indulo(2,3-a)quinolizidines,preparation and therapeutic use
FR2713644B1 (fr) * 1993-12-14 1996-02-09 Adir Nouveaux analogues de l'éburnane, leur procédé de préparation et les compositions pharmaceutiques qui les contiennent.
DE60307049T2 (de) * 2003-04-25 2007-02-08 Neuro3D Verwendung von Piperazin- Phenothiazin- Derivaten zur Herstellung eines Arzneimittels mit neuroprotektiven und/oder neurotropischen Wirkungen auf das ZNS und/oder PNS
CN1566099A (zh) * 2003-06-13 2005-01-19 中国科学院上海药物研究所 异喹啉－1,3,4－三酮类化合物、制备方法及其用途

Also Published As

Publication number Publication date
KR20090104853A (ko) 2009-10-06
EA200900923A1 (ru) 2009-12-30
JP2010514827A (ja) 2010-05-06
US20090298813A1 (en) 2009-12-03
WO2008099083A2 (fr) 2008-08-21
BRPI0806275A2 (pt) 2011-09-06
CA2674100A1 (fr) 2008-08-21
WO2008099083A3 (fr) 2008-12-11
CN101578100A (zh) 2009-11-11
AU2008214550A1 (en) 2008-08-21
EP2101768A2 (fr) 2009-09-23
AR064749A1 (es) 2009-04-22
FR2911143A1 (fr) 2008-07-11
MA31032B1 (fr) 2009-12-01

Similar Documents

Publication Publication Date Title
EP2318005A4 (en) NEUROPROTECTIVE AGENTS FOR THE PREVENTION AND TREATMENT OF NEURODEEGENERATIVE DISEASES
HK1224200A1 (zh) 用於治療胰腺癌的藥物
MX2012006730A (es) Tiazolidinadionas moderadoras de receptores activados por proliferador de peroxizoma (ppar) y combinaciones para tratamiento de enfermedades neurodegenerativas y otras enfermedades metabolicas.
MX2009006704A (es) Derivados de amina triciclicos como inhibidores de proteina de tirosina cinasa.
PT2322221E (pt) Composição farmacêutica para tratamento e prevenção de cancro
TNSN08400A1 (en) Organic compounds and their uses
EP2493464A4 (en) METHYLSULFONYLMETHANE (MSM) FOR THE TREATMENT OF DRUG-RESISTANT MICROORGANISMS
EP2099448A4 (en) PHARMACEUTICAL COMPOSITION FOR THE TREATMENT AND PREVENTION OF RESTENOSIS
EP2421367A4 (en) ALLANTOIN ADMINISTRATION FOR THE TREATMENT OF NEURODEGENERATIVE DISEASE AND NEUROLOGICAL TRAUMATISM
MX2009010407A (es) Derivados fluorados de deferiprona.
MX2009006327A (es) Compuestos heterociclicos y metodos de uso de los mismos.
ZA200906165B (en) Treatment and prevention of neurodegenerative diseases using gene therapy
ZA201200944B (en) Pharmaceutical compositions for the treatment of cancer and other diseases or disorders
EP2206714A4 (en) AGENT FOR THE PREVENTION AND / OR TREATMENT OF SKIN DISEASES
MX2010003269A (es) Derivados de pirrolotriazina utiles para tratar cancer a traves de la inhibicion de la aurora quinasa.
HK1145994A1 (zh) 苦瓜中提取的化合物在製備預防和治療糖尿病和肥胖的藥物中的用途
EP2473037A4 (en) METHOD OF TREATING NEURODEGENERATIVE OR DEGENERATIVE NEUROMUSCULAR DISEASES AND THERAPEUTIC AGENT FOR TREATING THESE DISEASES
EP2001488A4 (en) PREVENTION AND TREATMENT OF CANCER AND OTHER DISEASES
EP2231148A4 (en) PHARMACEUTICAL COMPOSITION FOR THE TREATMENT AND PREVENTION OF CARDIAC DISEASE
MX2009013482A (es) Derivados de [1,10]-fenantrolina para el tratamiento de enfermedades neurodegenerativas o hematologicas.
EP2231146A4 (en) Pharmaceutical composition for the treatment and prevention of glaucoma
MX2009007198A (es) Uso de compuestos neuroprotectores para obtener medicamentos destinados al tratamiento de enfermedades neurodegenerativas.
EP2305300A4 (en) PHARMACEUTICAL COMPOSITION FOR THE TREATMENT AND PREVENTION OF CANCER
EP2222295A4 (en) PHARMACEUTICAL COMPOSITION FOR THE TREATMENT AND PREVENTION OF RENAL DISEASES
EP2127673A4 (en) PHARMACEUTICAL AGENT FOR THE PREVENTION AND TREATMENT OF SKIN DISORDERS BY ACCELERATED KERATINISATION

Legal Events

Date Code Title Description
FA Abandonment or withdrawal